86.90.E - Other human health activities notelsewhere classified
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
73.1 - Advertising
73.20.Z - Market research and public opinion polling
75.00.Z - Veterinary activities
85.59.B - Other out-of-school forms of education, not elsewhere classified
86.22.Z - Specialist medical practice activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 37,4 | 15,5 | -318,2 | -2148,3 |
EBITDA | 43,6 | 26,1 | -313,8 | -1301 |
Short time liabilities | 7,1 | 5,8 | 4,7 | -20 |
Equity capital | 333,9 | 348 | 29,8 | -91,4 |
Operating profit (EBIT) | 37,4 | 15,6 | -318,2 | -2136 |
Assets | 341 | 353,8 | 55 | -84,4 |
Net profit (loss) | 33,9 | 14 | -318,2 | -2365,4 |
Cash | 312,7 | 311,7 | 51,8 | -83,4 |
Net income from sale | 464,8 | 624,5 | 5,5 | -99,1 |
Liabilities and provisions for liabilities | 7,1 | 5,8 | 25,2 | 331,5 |
Working assets | 326,1 | 349,5 | 55 | -84,2 |
Depreciation | 6,1 | 10,5 | 4,4 | -58,3 |
% | % | % | p.p. | |
Profitability of capital | 10,2 | 4 | -1066,5 | -1070,5 |
Equity capital to total assets | 97,9 | 98,3 | 54,2 | -44,1 |
Gross profit margin | 8,1 | 2,5 | -5776,3 | -5778,8 |
EBITDA Margin | 9,4 | 4,2 | -5696,9 | -5701,1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 6 | 3 | 310 | 307 |
Current financial liquidity indicator | 46.162086486816406 | 59.81217956542969 | 2.1832385063171387 | -57,6 |
Net dept to EBITDA | -7.178718566894531 | -11.930159568786621 | 0.16500337421894073 | 12,1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane